Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair Coles(University of Cambridge), Cary Twyman(Associates in Neurology), Douglas L. Arnold(NeuroRx Research (Canada)), Jeffrey Cohen(Cleveland Clinic), Christian Confavreux(Université Claude Bernard Lyon 1), Edward Fox(Central Texas Neurology Consultants), Hans-Peter Hartung(Heinrich Heine University Düsseldorf), Eva Havrdová(Charles University), Krzysztof Selmaj(Medical University of Lodz), Howard L. Weiner(Brigham and Women's Hospital), Tamara Miller, Elizabeth Fisher(Cleveland Clinic), Rupert Sandbrink(Bayer (Germany)), Stephen Lake, David Margolin, Pedro Oyuela, Michael Panzara, D. A. S. Compston(University of Cambridge)
Cited by 1,193Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis